Wiley-VCH, Weinheim Modern Biopharmaceuticals Cover A unique and comprehensive introduction to recently developed technologies, showing paradigm shifts .. Product #: 978-3-527-31184-2 Regular price: $794.39 $794.39 In Stock

Modern Biopharmaceuticals

Design, Development and Optimization

Knäblein, Jörg (Editor)

Cover

1. Edition August 2005
1886 Pages, Hardcover
501 Pictures (124 Colored Figures)
158 tables
Handbook/Reference Book

ISBN: 978-3-527-31184-2
Wiley-VCH, Weinheim

Short Description

A unique and comprehensive introduction to recently developed technologies, showing paradigm shifts in the health care system and how these changes are reflected in industrial research. With authors from the world's most famous academic institutes and biotech companies.

Buy now

Price: 850,00 €

Price incl. VAT, excl. Shipping

The biopharmaceutical market has come along way since 1982 when the first biopharmaceutical product, recombinant human insulin, was launched.
Over 120 such products are currently being marketed around the world including nine blockbuster drugs. The global market for biopharmaceuticals, which is currently valued at US$41 billion, has been growing at an impressive compound annual growth rate of 21% over the previous five years.

With over one third of all pipe-line products in active development are biopharmaceuticals, this segment is set to continue outperforming the total pharmaceutical market and could easily reach US$100 billion by the end of this decade.

Volume 1

INTRODUCTION
PART I: BIOPHARMACEUTICALS USED IN MOLECULAR MEDICINE
Genes & genomes - correlation between genes, diseases & biopharmaceuticals
siRNA - the magic bullet & other gene therapeutical approaches
Mobilis in mobile - human embryonic stem cells & other sources for cell therapy


Volume 2

PART II: BIOPHARMACEUTICALS AND THEIR MODE OF ACTION
The clotting cascade - lysis, coagulation & a fine-tuned balance
Errare humanum est - what causes cancer & how to selectively fight tumors
Mundus vult decipi - high mutation rates of HIV & new paradigms for treatment
PART III: IMPROVING THE DEVELOPMENT OF BIOPHARMACEUTICALS
Citius, altius, fortius - acceleration by high throughput & ultra-HT
Early target validation - knock-out mice & more
Revolution by evolution - rational design for desire & the scientific art of optimization


Volume 3

PART IV: PRODUCTION OF BIOPHARMACEUTICALS
The industry's workhorses - mammalian expression systems
A ripe and blooming market - biopharmaceuticals from transgenic animals & plants
Alea non iacta est - improving established expression systems
When success raises its ugly head - outsourcing to uncork the capacity bottleneck
PART V: BIOPHARMACEUTICALS USED FOR DIAGNOSTICS AND IMAGING
From hunter to craftsman - engineering antibodies with nature's universal toolbox
Find, fight & follow - target-specific troica from Mother Nature's Pharmacopoiea
Getting insight - sense the urgency for early diagnostics


Volume 4

PART VI: ADVANCED APPLICATION ROUTES FOR BIOPHARMACEUTICALS
Getting inside - quest for the best & how to improve delivery
Pathfinder - new ways for peptides, proteins & Co
Via mala - the stony road of DNA delivery: back-pack, feed-back & pay-back
Getting beyond - rocket science & science fiction
PART VII: FROM TRANSCRIPTION TO PRESCRIPTION
Opening the therapeutic window - between systemic toxicity & lack of efficacy
Happy end - claim to fame & approval
PART VIII: FROM BENCH TO BEDSIDE - THE AFTERMATHS
Think big & dealmaking for growth - global changes in the health-care sector
News & views - quo vadis, biopharmaceuticals?
Small molecules - light at the end of the tunnel or back to the roots?
"... an authoritative sourcebook dealing with the entire broad range of biopharmaceuticals now available. ... an impressive compilation of outstanding results written by brilliant, creative thinkers who are shaping present and future biotechnology. I am pleased to recommend strongly this complete and comprehensive basic reference source for this new, exciting field to biotechnologists, clinicians, physicians, pharmacists, pharmaceutical chemists, molecular biologists, medicinal chemists, and anyone working in the biotechnological and pharmaceutical industries or in medicinal institutes. It should also be invaluable to undergraduate and graduate students, postdoctoral fellows, and researchers looking for quick, clear, and concise ideas on topics that lie outside their areas of expertise. It also belongs in academic, industrial, and governmental libraries."
The Chemical Educator

"This is an extensive and unmatched compilation of comprehensive, in-depth current knowledge and history of biopharmaceuticals...the author is commended for this grand effort." Veterinary Pathology

"I heartly recommend this authoritative, comprehensive reference to this new, exciting field dealing with the entire broad range of available biopharmaceuticals. It will be invaluable to biotechnologists, clinicians, physicians, pharmacists, pharmaceutical chemists, molecular biologists, medicinal chemists and anyone working in the biotechnological and pharmaceutical industries or in medicinal institutes. It should be also be useful for undergraduate and graduate students, postdoctoral fellows, and researchers seeking quick, clear, and concise ideas on topics outside their areas of specialization. it should also find a place in academic, industrial, and governmental libraries."
ChemMedChem

"All in all, this is an impressive snapshot of the field." Journal of Medicinal Chemistry

"... the four volumes represent a highly valuable reference compendium for any practicing scientists interested in this sector of biotechnology."
Chemistry and Industry

"Due to the impressive accumulation of outstanding results, presented by brilliant, privileged and creative thinkers, the book reads like the Who is Who of biotechnology. Never before has such an impressive group of individuals contributed to one biotechnology book, including Nobel Prize laureates Robert Huber, Thomas R. Cech, and Manfred Eigen as well as authors from the world's most famous academic institutes and biotech companies." BIOforum Europe
Dr. Jörg Knäblein studied Biotechnology / Chemical Engineering at the Society for Biotechnology Research (GBF) in Braunschweig, Germany and Biochemistry at the Max-Planck-Institute for Biochemistry. He received his Ph.D. from the Max-Planck-Institute for Biochemistry in Martinsried / Munich where he worked in the group of Professor Huber (Nobelprize laureate in 1988).

AWARDS:
Riedel-de Haen-Stiftung
Government / Ministry of Science
Nomination for the Max-Buchner-Award from DECHEMA (Society for Biotechnology and Chemical Engineering)
Winner of the McKinsey business plan contest

J. Knäblein, Schering AG, Berlin, Germany